Abstract: An isolated cell having the characteristics of the cell line designated FO-1 #12 is provided. The cell FO-1 #12 is characterized as being .beta..sub.2 -microglobulin-deficient, neomycin-resistant and HAT-sensitive. A cell hybrid formed by the fusion of an FO-1 #12 cell or other cell described herein and a mammalian cell is provided. The patient-derived cell can be a tumor cell or other cell, such as a white blood cell. The patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, or others. A method of treating AIDS in a patient, comprising administering to the patient a cell hybrid provided herein, wherein the patient-derived white blood cell is derived from the patient being treated, is provided.

Abstract: The invention is directed to a method of increasing ionizing radiation's cytotoxic effects on a neoplasm in a subject by increasing the neoplasm's sensitivity to ionizing radiation, comprising administering a therapeutically effective amount of prostaglandin to the subject, and subjecting the neoplasm to a therapeutically effective amount of ionizing radiation, thereby increasing the cytotoxic effects of the ionizing radiation on the neoplasm.